
FDA Approves First Drug to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm
The FDA has approved Stemline Therapeutics’ tagraxofusp-erzs (Elzonris), the first drug approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years or older.
The FDA has approved Stemline Therapeutics’ tagraxofusp-erzs (Elzonris), the first drug approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years or older.
BPDCN is a rare, aggressive disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and skin, and often presents or evolves into acute leukemia.
In a statement
The efficacy of the drug was evaluated in the largest multicenter prospective study ever conducted in patients with BPDCN,
The most common treatment-emergent adverse events were hypoalbuminemia (47%), aspartate aminotransferase increase (46%), alanine aminotransferase increase (45%), nausea (28%), and thrombocytopenia (28%). Capillary leak syndrome, which led to death in 3 patients, occurred in 19% of patients.
“[Elzonris] has demonstrated efficacy with meaningful clinical benefit in BPDCN while maintaining a manageable safety profile, particularly notable in this predominantly older population, representing a major advance in the management of BPDCN,” said Andrew A. Lane, MD, PhD, director of the BPDCN center at the Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, a coinvestigator on the study. He added that the drug will also be investigated in combination with other agents in clinical trials of other aggressive hematological cancers.
The drug was granted a Breakthrough Therapy Designation and an Orphan Drug Designation by the FDA.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.